Regulatory hub · UK status
Semaglutide: UK regulatory status
Also known as: Wegovy, Ozempic, Rybelsus
Last reviewed . Editorial commentary, not legal advice.
AI-friendly summary · Semaglutide
Semaglutide is a Prescription Only Medicine in the UK with MHRA marketing authorisation for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). It is not a controlled drug. POM advertising rules apply.
Misuse of Drugs Act 1971
Semaglutide does not appear on any schedule of the Misuse of Drugs Act 1971.
Psychoactive Substances Act 2016
Semaglutide is not covered by the Psychoactive Substances Act 2016.
MHRA and medicines classification
Semaglutide is a Prescription Only Medicine. Wegovy is licensed for chronic weight management; Ozempic and Rybelsus are licensed for type 2 diabetes. Dispensed through registered UK pharmacies on a valid prescription. MHRA has issued enforcement notices to UK sellers marketing unlicensed semaglutide for weight loss.
WADA Prohibited List position
Semaglutide is not currently named on the WADA Prohibited List. Tested athletes should consult WADA and their federation directly.
ASA advertising framing
POM advertising to the public is prohibited under the Human Medicines Regulations 2012. ASA has upheld multiple rulings against UK clinics naming Wegovy or Ozempic in paid promotion.
Primary sources
When in doubt about your specific position, consult MHRA directly via the MHRA contact page or seek qualified UK medicines law advice.
Frequently asked questions
Is Semaglutide legal in the UK?
What is the MHRA position on Semaglutide?
Is Semaglutide on the WADA Prohibited List?
What can UK sellers say about Semaglutide in adverts?
Related: Semaglutide editorial entry · UK regulatory hub.